Thrombosis research最新文献

{"title":"Rate and predictors of thromboprophylaxis in internal medicine wards: Results from the AURELIO study","authors":"Arianna Magna , Enrico Maggio , Gianpaolo Vidili , Angela Sciacqua , Chiara Cogliati , Rosella Di Giulio , Sciaila Bernardini , Alessia Fallarino , Ilaria Maria Palumbo , Arianna Pannunzio , Chiara Bagnato , Carla Serra , Maria Boddi , Lorenzo Falsetti , Vincenzo Zaccone , Evaristo Ettorre , Giovambattista Desideri , Luca Santoro , Vito Cantisani , Pasquale Pignatelli , Marco Domenicali","doi":"10.1016/j.thromres.2024.109148","DOIUrl":"10.1016/j.thromres.2024.109148","url":null,"abstract":"<div><h3>Background</h3><div>Randomized controlled trials suggest that prophylactic doses of anticoagulants effectively prevent venous thromboembolism (VTE) in hospitalized medical patients with high thromboembolic risk. However, no prospective studies exist regarding the real-world prevalence of prophylactic anticoagulant use. This prospective study aimed to determine the rate and predictors of thromboprophylaxis in an unselected population of patients hospitalized in medical departments.</div></div><div><h3>Methods</h3><div>We conducted a multicenter prospective observational study (AURELIO – rAte of venous thrombosis in acutely iLl patIents hOspitalized) to assess the rate of deep vein thrombosis (DVT) in unselected acutely ill patients hospitalized in medical wards using compression ultrasound (CUS) at admission and discharge. Additionally, we evaluated the rate of pharmacological thromboprophylaxis administration in this population and analyzed the thrombotic risk by assessing RAMs (Risk Assessment Models) such as the IMPROVE-VTE and PADUA scores following the clinician's decision to administer thromboprophylaxis. Patients with IMPROVE-VTE scores ≥3 and/or PADUA scores ≥4 were classified as high thrombotic risk; those with IMPROVE-VTE scores <3 and/or PADUA scores <4 were classified as low risk.</div></div><div><h3>Results</h3><div>We recruited 2371 patients (1233 males [52 %] and 1138 females [48 %]; mean age 72 ± 16 years). The median length of hospitalization was 13 ± 12 days. Overall, 442/2371 (18.6 %) patients received prophylactic parenteral anticoagulants (subcutaneous low weight molecular heparin or fondaparinux once daily) at admission. Assessing the thrombotic risk of the population recruited 1016 (42.9 %) patients were classified as high risk and 1354 (57.1 %) were low risk. Among high-risk patients, 339/1016 (33.4 %) received anticoagulant prophylaxis compared to 103/1354 (7.6 %) low-risk patients. During hospitalization, 9 patients developed DVT, comprising 7 asymptomatic and 2 symptomatic cases of proximal DVT. Of these, 3 patients were on anticoagulant prophylaxis, while 6 were not. Among the high-risk population, 7 out of 1016 patients (0.7 %) experienced proximal DVT during hospitalization, with 2 out of these 7 (28 %) receiving anticoagulant thromboprophylaxis. In the low-risk population, 2 out of 1354 patients (0.2 %) developed DVT, with 1 out of these 2 (50 %) receiving anticoagulant thromboprophylaxis. Age, heart or respiratory failure, pneumonia, active neoplasia, previous VTE, reduced mobility, and absence of kidney failure were more frequent in patients receiving prophylaxis. Multivariable logistic regression identified age (RR 1.010; CI 95 % 1002–1019; <em>p</em> = 0.015), heart/respiratory failure (RR 1.609; CI 95 % 1248–2075; <em>p</em> < 0.0001), active neoplasia (RR 2.041; CI 95 % 1222–2141; p < 0.0001), pneumonia (RR 1.618; CI 95 % 1557–2676; p < 0.0001), previous VTE (RR 1.954; CI 95 % 1222–3125;","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"243 ","pages":"Article 109148"},"PeriodicalIF":3.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142318637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of IVF treatments in women with antiphospholipid antibodies or antiphospholipid syndrome","authors":"Michal Mia Shalamov ,&nbsp;Lichay Kaufman ,&nbsp;Michal J. Simchen ,&nbsp;Nancy Agmon-Levin ,&nbsp;Mudi Misgav ,&nbsp;Raoul Orvieto ,&nbsp;Ronit Machtinger","doi":"10.1016/j.thromres.2024.109144","DOIUrl":"10.1016/j.thromres.2024.109144","url":null,"abstract":"<div><h3>Background</h3><p>Ovulation induction for in vitro fertilization (IVF) may increase intravascular thromboses among patients with antiphospholipid autoantibodies (aPLs) or antiphospholipid syndrome (APS) due to the high estrogen levels. While natural or modified natural IVF treatment cycles (MNC) are sometimes used instead of stimulated cycles with empiric anticoagulant treatment among these infertile patients, their efficacy is unclear.</p></div><div><h3>Materials and methods</h3><p>A retrospective cohort study including all IVF cycles of patients diagnosed with aPLs or APS in a tertiary, university-affiliated hospital between 2012 and 2022. The outcomes of stimulated cycles with anticoagulants and MNC and natural IVF cycle attempts were compared.</p></div><div><h3>Results</h3><p>121 oocyte retrievals from 38 women were analyzed: 93 stimulated and 28 MNC or natural IVF cycles. The rates of cycle cancellation (0 % vs. 17.9 %, <em>p</em> &lt; 0.001) and cycles in which no oocytes were retrieved (0 % vs. 43.5 %, p &lt; 0.001) were significantly lower following stimulated cycles vs. natural and MNC. In parallel, positive β-hCG (31.9 % vs. 10.9 %, <em>p</em> = 0.03), clinical pregnancy rate (23.6 % and 3.6 %, <em>p</em> &lt; 0.001) and live birth rates (18.1 % vs. 3.6 %, <em>p</em> = 0.01) were significantly higher following stimulated cycles. No thrombotic events or bleeding occurred in any cycle.</p></div><div><h3>Conclusion</h3><p>Ovarian stimulation for IVF is more effective for successful pregnancy and delivery than natural cycles and MNC and can be safely undertaken in aPLs or APS women undergoing IVF. Rates of complication from hormonal treatment are not increased when treated with LMWH during ovarian stimulation.</p></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"243 ","pages":"Article 109144"},"PeriodicalIF":3.7,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142233730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accurately identifying incident cases of venous thromboembolism in the electronic health record: Performance of a novel phenotyping algorithm","authors":"Ania Syrowatka ,&nbsp;Avery Pullman ,&nbsp;Elizabeth Pajares ,&nbsp;Kyra White ,&nbsp;Michael Sainlaire ,&nbsp;Jin Chen ,&nbsp;Frank Chang ,&nbsp;Krissy Gray ,&nbsp;John Laurentiev ,&nbsp;Wenyu Song ,&nbsp;Tien Thai ,&nbsp;Li Zhou ,&nbsp;Stuart R. Lipsitz ,&nbsp;David W. Bates ,&nbsp;Lipika Samal ,&nbsp;Patricia C. Dykes","doi":"10.1016/j.thromres.2024.109143","DOIUrl":"10.1016/j.thromres.2024.109143","url":null,"abstract":"<div><h3>Background</h3><p>Accurate identification of incident venous thromboembolism (VTE) for quality improvement and health services research is challenging. The purpose of this study was to evaluate the performance of a novel incident VTE phenotyping algorithm defined using standard terminologies, requiring three key indicators documented in the electronic health record (EHR): VTE diagnostic code, VTE-related imaging procedure code, and anticoagulant medication code.</p></div><div><h3>Methods</h3><p>Retrospective chart reviews were conducted to assess the performance of the algorithm using a random sample of phenotype(+) and phenotype(−) diagnostic encounters from primary care practices and acute care sites affiliated with five hospitals across a large integrated care delivery system in Massachusetts. The performance of the algorithm was evaluated by calculating the positive predictive value (PPV), negative predictive value (NPV), sensitivity, and specificity, using the phenotype(+) and phenotype(−) diagnostic encounters sample and target population data.</p></div><div><h3>Results</h3><p>Based on gold-standard manual chart review, the algorithm had a PPV of 95.2 % (95 % CI: 93.1–96.8 %), NPV of 97.1 % (95 % CI: 95.3–98.4 %), sensitivity of 91.7 % (95 % CI: 90.8–92.6 %), and specificity of 98.4 % (95 % CI: 98.1–98.6 %). The algorithm systematically misclassified a low number of specific types of encounters, highlighting potential areas for improvement.</p></div><div><h3>Conclusions</h3><p>This novel phenotyping algorithm offers an accurate approach for identifying incident VTE in general populations using EHR data and standard terminologies, and accurately identifies the specific encounter and date of diagnosis of the incident VTE. This approach can be used for measurement of incident VTE to drive quality improvement, research to expand the evidence, and development of quality metrics and clinical decision support to improve the diagnostic process.</p></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"243 ","pages":"Article 109143"},"PeriodicalIF":3.7,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142272020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge and raising awareness are the CURES for alleviating sex disparities in PE care","authors":"Behnood Bikdeli ,&nbsp;Shannon M. Bates","doi":"10.1016/j.thromres.2024.109147","DOIUrl":"10.1016/j.thromres.2024.109147","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"243 ","pages":"Article 109147"},"PeriodicalIF":3.7,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142230776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex disparities of clinical manifestations in acute pulmonary embolism and predictive value for in-hospital mortality: Insights from CURES","authors":"Han Tian ,&nbsp;Yu Zhang ,&nbsp;JiXiang Liu ,&nbsp;Yuanhua Yang ,&nbsp;Yingqun Ji ,&nbsp;Hong Chen ,&nbsp;Dingyi Wang ,&nbsp;Zhu Zhang ,&nbsp;Qun Yi ,&nbsp;Chunling Dong ,&nbsp;Xiaomao Xu ,&nbsp;Xiaoyun Hu ,&nbsp;Yimin Mao ,&nbsp;Ling Zhu ,&nbsp;Zhihong Liu ,&nbsp;Juhong Shi ,&nbsp;Chaosheng Deng ,&nbsp;Zhe Cheng ,&nbsp;Yunxia Zhang ,&nbsp;Meng Zhang ,&nbsp;Zhenguo Zhai","doi":"10.1016/j.thromres.2024.109146","DOIUrl":"10.1016/j.thromres.2024.109146","url":null,"abstract":"<div><h3>Background</h3><p>Pulmonary embolism (PE) is a common and potentially fatal disease, with differences in mortality rates among PE patients of different sexes. This study aims to investigate the disparities in clinical manifestations and in-hospital mortality rates between sexes in PE patients, as well as the association of clinical symptoms with in-hospital mortality.</p></div><div><h3>Methods</h3><p>We analyzed data from the China pUlmonary thromboembolism REgistry Study (CURES), a nationwide, multicenter, prospective registry focusing on patients with acute PE. Using propensity score matching (PSM) to pair male and female patients with PE, we explored the correlation between clinical symptoms and in-hospital mortality through multivariable regression analysis.</p></div><div><h3>Results</h3><p>A total of 15,203 patients with acute PE were enrolled, and 380 died during hospitalization. The incidence of chest pain, hemoptysis, and palpitations was significantly higher in males compared to females. The incidence of dyspnea, fever, and syncope was higher in females. Hemoptysis and dyspnea were associated with increased in-hospital mortality in males, whereas dyspnea, fever, and palpitations were linked to higher mortality in females. Overall, males exhibited a higher in-hospital mortality than females (2.9 % vs. 2.1 %, <em>p</em> = 0.002). After matching 13,130 patients using the PSM method, the mortality rate of males remained higher than that of females (2.7 % vs. 2.1 %, <em>p</em> = 0.020).</p></div><div><h3>Conclusions</h3><p>Our study demonstrates that male patients with PE have a higher risk of in-hospital mortality than females. Significant differences in clinical symptoms between sexes are associated with increased mortality risk, emphasizing the need for clinical awareness.</p></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"243 ","pages":"Article 109146"},"PeriodicalIF":3.7,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142150925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of venous thromboembolism and adequacy of thromboprophylaxis in 2380 acutely-ill hospitalized patients: Results from the PROFMiG cohort study","authors":"Bruno Ávila Ferreira ,&nbsp;Pedro Luiz Lage Bodour Danielian ,&nbsp;Geovanna Cota Caetano ,&nbsp;Cássia Rodrigues Lima Ferreira ,&nbsp;Maria Aparecida de Oliveira ,&nbsp;Enrico Antônio Colosimo ,&nbsp;Marcos de Bastos ,&nbsp;Suely Meireles Rezende","doi":"10.1016/j.thromres.2024.109145","DOIUrl":"10.1016/j.thromres.2024.109145","url":null,"abstract":"<div><h3>Introduction</h3><p>Hospital-acquired venous thromboembolism (VTE) is a major cause of preventable deaths. Incidence of VTE and adequacy of thromboprophylaxis have rarely been reported in low-resourced countries. The aim of this study was to estimate the incidence of VTE and to evaluate the adequacy of thromboprophylaxis in acutely-ill medical hospitalized patients.</p></div><div><h3>Methods</h3><p>The PROFMiG is a prospective cohort study conducted in Brazil. We consecutively enrolled adult (&gt; 18 years) acutely-ill hospitalized medical patients at admission. Risk assessment for VTE was evaluated by the IMPROVE7 (<em>International Medical Prevention Registry on Venous Thromboembolism</em>). Outcomes were death and VTE events during hospital stay up to 90 days after discharge. All VTE and death events were adjudicated. We also evaluated pulmonary embolism-related death and adequacy of thromboprophylaxis. VTE incidence was estimated by competing risk methods.</p></div><div><h3>Results</h3><p>A total of 2380 participants was included. Median age was 70 years, 56.1 % women, median length of hospital stay was 10 days. A total of 2052 (86.3 %) patients were classified as low-risk for VTE, 30 (1.3 %) patients had objectively confirmed VTE, and 1449 (60.8 %) received inadequate thromboprophylaxis. The overall mortality rate was 14.0 %. Cumulative incidence of VTE was 2.0 % (95 % confidence interval 0.9 %–3.8 %) at 130 days after admission when considering death as competing risk.</p></div><div><h3>Conclusion</h3><p>The cumulative incidence of VTE in this cohort corroborates with that reported in high-resourced countries. Despite recommendation, thromboprophylaxis was mostly inadequate. We suggest the adoption of competing risk analysis to estimate the cumulative incidence of VTE in hospitalized patients.</p></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"243 ","pages":"Article 109145"},"PeriodicalIF":3.7,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142150924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tocilizumab reduces hypercoagulation in COVID-19 – Perspectives from the coagulation and immunomodulation Covid assessment (Coag-ImmCovA) clinical trial","authors":"Lou M. Almskog ,&nbsp;Anna Sjöström ,&nbsp;Jonas Sundén-Cullberg ,&nbsp;Apostolos Taxiarchis ,&nbsp;Anna Ågren ,&nbsp;Sara Freyland ,&nbsp;Madeleine Börjesson ,&nbsp;Agneta Wikman ,&nbsp;Carl Magnus Wahlgren ,&nbsp;Michael Wanecek ,&nbsp;Jan van der Linden ,&nbsp;Jovan Antovic ,&nbsp;Jon Lampa ,&nbsp;Maria Magnusson","doi":"10.1016/j.thromres.2024.109135","DOIUrl":"10.1016/j.thromres.2024.109135","url":null,"abstract":"<div><h3>Background</h3><p>Despite medical interventions, COVID-19 continues to persist at pandemic proportions. A hypercoagulation state was rapidly observed in the severely ill, and the incidence of thromboembolic events remains elevated. Interleukin inhibitors have demonstrated positive effects on the hyperactivation of the immune system in COVID-19, with the interleukin-6 inhibitor tocilizumab showing promising results in reducing mortality. Nevertheless, the impact of interleukin inhibitors on the coagulation system remains incompletely understood.</p></div><div><h3>Methods</h3><p>In this clinical trial conducted in Stockholm, Sweden, interleukin inhibitors, namely anakinra (ANA) or tocilizumab (TOCI), were randomly administered in addition to standard care (SC) to hospitalized patients with COVID-19. A control group received only SC. The primary outcome sought to measure effects on global hemostasis, as indicated by changes in functional coagulation tests, specifically Rotational Thromboelastometry (ROTEM) or Overall Hemostatic Potential (OHP), visualized through scanning electron microscopy images. Secondary outcomes included effects on conventional coagulation laboratory tests.</p></div><div><h3>Results</h3><p>The study enrolled 74 patients who were randomized to receive either ANA or TOCI in addition to SC, or SC alone. In the TOCI group, ROTEM variables exhibited less hypercoagulation after 29 days compared with ANA or SC treatment groups, characterized by prolonged clot formation time and decreased clot firmness. OHP decreased, but there were no significant differences among the three treatment groups. Plasma fibrinogen levels, initially elevated, decreased significantly in TOCI recipients over time.</p></div><div><h3>Conclusion</h3><p>Tocilizumab treatment demonstrated a significant reduction of hypercoagulation in hospitalized COVID-19 patients, by improvements in both global coagulation tests and conventional laboratory tests, in comparison with anakinra or SC alone. This finding underscores the significance of tocilizumab as a viable treatment option in severe COVID-19 cases, with the potential to decrease thrombosis incidence.</p></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"243 ","pages":"Article 109135"},"PeriodicalIF":3.7,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142121725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TO INFORM OR NOT TO INFORM about venous thromboembolisms – A qualitative study on communication between healthcare professionals and patients with lung cancer","authors":"Camilla Berggreen ,&nbsp;Jonas Hermann Schrøder ,&nbsp;Thomas Christensen ,&nbsp;Weronika Maria Szejniuk ,&nbsp;Mette Søgaard ,&nbsp;Anette Arbjerg Højen ,&nbsp;Lone Jørgensen","doi":"10.1016/j.thromres.2024.109132","DOIUrl":"10.1016/j.thromres.2024.109132","url":null,"abstract":"<div><h3>Background</h3><p>Venous thromboembolism (VTE) is a leading cause of death among cancer patients. Despite this, studies show that patients with cancer feel inadequately informed about the VTE risk and symptoms, which may impede their ability to recognise symptoms and react promptly. Patients with lung cancer are especially vulnerable due to a high relative risk of developing VTE combined with a high prevalence of low health literacy. This study aimed to explore the VTE information needs of lung cancer patients and how patients and healthcare professionals (HCPs) communicate about VTE.</p></div><div><h3>Material and methods</h3><p>Data was collected via semi-structured interviews with patients with lung cancer and HCPs. All participants (<em>n</em> = 20) were recruited from an oncological department. The analysis was performed in an inductive manner using a Ricoeur inspired strategy.</p></div><div><h3>Findings</h3><p>Patients had varying information needs regarding VTE, but HCPs did not routinely communicate about VTE, as the topic tended to be lowly prioritised. HCPs communicated about VTE when patients expressed a need or presented symptoms of VTE. HCPs expressed concerns about adding to patient's emotional burden by informing about VTE, while some patients emphasised the importance of being mentally prepared for potential complications.</p></div><div><h3>Conclusion</h3><p>The study demonstrates the challenging balance HCPs must maintain between adequately communicating about VTE and not causing undue psychological distress. However, given patient's often limited awareness of VTE, the responsibility to initiate communication about VTE must fall on the HCPs.</p></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"243 ","pages":"Article 109132"},"PeriodicalIF":3.7,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0049384824002640/pdfft?md5=9ece8be26f2abd8b2553e966058f9ec2&pid=1-s2.0-S0049384824002640-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142163981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Inhibitory effects of resveratrol on platelet activation and thrombosis in colon cancer through regulation of the MAPK and cGMP/VASP pathways” [Thromb. Res. 2024 Aug 2:241:109111]","authors":"Ze Yu ,&nbsp;Wenwen Zhu ,&nbsp;Fengyan Lu ,&nbsp;Hong Liu ,&nbsp;Haitao Sun ,&nbsp;Jinliang Dong ,&nbsp;Yingjie Zhang ,&nbsp;Hongqiang Wang","doi":"10.1016/j.thromres.2024.109131","DOIUrl":"10.1016/j.thromres.2024.109131","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"242 ","pages":"Article 109131"},"PeriodicalIF":3.7,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0049384824002639/pdfft?md5=74e7849ba730c31589fd994ed66ecc6a&pid=1-s2.0-S0049384824002639-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142087055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulation of fibrinogen synthesis","authors":"Dre'Von A. Dobson ,&nbsp;Richard J. Fish ,&nbsp;Paul S. de Vries ,&nbsp;Alanna C. Morrison ,&nbsp;Marguerite Neerman-Arbez ,&nbsp;Alisa S. Wolberg","doi":"10.1016/j.thromres.2024.109134","DOIUrl":"10.1016/j.thromres.2024.109134","url":null,"abstract":"<div><p>The plasma protein fibrinogen is encoded by 3 structural genes (<em>FGA</em>, <em>FGB</em>, and <em>FGG</em>) that are transcribed to mRNA, spliced, and translated to 3 polypeptide chains (Aα, Bβ, and γ, respectively). These chains are targeted for secretion, decorated with post-translational modifications, and assembled into a hexameric “dimer of trimers” (AαBβγ)₂. Fully assembled fibrinogen is secreted into the blood as a 340 kDa glycoprotein. Fibrinogen is one of the most prevalent coagulation proteins in blood, and its expression is induced by inflammatory cytokines, wherein circulating fibrinogen levels may increase up to 3-fold during acute inflammatory events. Abnormal levels of circulating fibrinogen are associated with bleeding and thrombotic disorders, as well as several inflammatory diseases. Notably, therapeutic strategies to modulate fibrinogen levels have shown promise in experimental models of disease. Herein, we review pathways mediating fibrinogen synthesis, from gene expression to secretion. Knowledge of these mechanisms may lead to the identification of biomarkers and new therapeutic targets to modulate fibrinogen in health and disease.</p></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"242 ","pages":"Article 109134"},"PeriodicalIF":3.7,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142098293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}